NASDAQ:GENB Generate Biomedicines Q2 2026 Earnings Report $17.14 +0.02 (+0.12%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$16.90 -0.23 (-1.37%) As of 09/18/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Generate Biomedicines EPS ResultsActual EPS-$0.52Consensus EPS -$0.48Beat/MissMissed by -$0.04One Year Ago EPSN/AGenerate Biomedicines Revenue ResultsActual Revenue$6.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGenerate Biomedicines Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Generate Biomedicines Earnings HeadlinesGenerate Biomedicines Inc (NASDAQ:GENB) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 20 at 2:44 AM | americanbankingnews.comGenerate Biomedicines (GENB) versus The Competition Head-To-Head ContrastSeptember 18 at 2:15 AM | americanbankingnews.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 20 at 1:00 AM | Paradigm Press (Ad)Contrasting Generate Biomedicines (GENB) & Its RivalsSeptember 17 at 5:16 AM | americanbankingnews.comGenerate Biomedicines (GENB) versus Its Rivals Critical ContrastSeptember 17 at 4:29 AM | americanbankingnews.comGenerate Biomedicines (GENB) versus The Competition Head to Head ContrastSeptember 15, 2026 | americanbankingnews.comSee More Generate Biomedicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Generate Biomedicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Generate Biomedicines and other key companies, straight to your email. Email Address About Generate BiomedicinesGenerate Biomedicines (NASDAQ:GENB) is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics. The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases. Its platform is designed to support the discovery and optimization of potential drug candidates, with programs directed toward proteins such as antibodies and other engineered therapeutics. Generate Biomedicines was founded as a Flagship Pioneering company and is based in the United States. The company combines computational biology, artificial intelligence and laboratory experimentation in an effort to accelerate the development of protein therapeutics for patients worldwide.View Generate Biomedicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
